Healthspan Capital

Healthspan Capital

Founded with a named focus on extending healthy human lifespan, Healthspan Capital channels capital into companies that tackle the underlying causes of age-related decline rather than isolated age-associated conditions. The firm operates out of El Cerrito, California, a location that places it within reach of the Bay Area's dense biotech and digital health startup ecosystem. Its investment activity centers on early-stage ventures — primarily seed and start-up rounds — where scientific risk is high but the potential to reshape how humans age is structurally transformative. Healthspan Capital's strategy allocates across a mix of biotech platform companies, AI-driven drug discovery for age-related diseases, and consumer-facing longevity interventions. The firm targets the translational gap where academic research in geroscience meets commercial viability, investing in therapeutics targeting cellular senescence, epigenetic reprogramming, and metabolic dysregulation. Its venture model favors direct equity positions in companies developing diagnostics that measure biological age alongside interventions that slow, halt, or reverse hallmark aging processes. The geographic footprint concentrates on North America, with a likely aperture to emerging longevity hubs in Europe and Asia. The firm's operational posture is typical of a specialist manager: a lean partnership structure running a concentrated portfolio of high-conviction bets. While specific team size and fund closes remain undisclosed, Healthspan Capital's presence in a niche where regulatory frameworks are still evolving suggests a model oriented toward patient capital and deep technical due diligence. The firm has not publicly disclosed any club deal structures, philanthropic vehicles, or multi-family office affiliations. Healthspan Capital's structural differentiator lies in its thesis purity. Unlike generalist healthtech or biotech funds that treat longevity as one of many verticals, the firm's entire mandate is calibrated to the biology of aging. This singular focus allows the investment team to underwrite scientific risk with a level of domain depth that broad-mandate peers may not replicate, positioning Healthspan Capital as a dedicated allocation vehicle for limited partners seeking targeted exposure to the geroscience revolution evolving alongside advances in AI, single-cell sequencing, and gene therapy.